Fresenius SE KGaA (XTRA:FRE) Expands Its Biosimilars Pipeline, Is The Stock Still Cheap?

Fresenius SE KGaA (XTRA:FRE) just paired a fresh earnings update with a large biosimilars development deal with WuXi Biologics, a combination that has sharpened investor focus on the stock.

Recent trading reflects that shift in sentiment. Fresenius SE KGaA has logged a 26.24% 1 month share price return and a 9.55% gain over the past week, with a 12.41% 1 year total shareholder return and a very large 3 year total shareholder return. This suggests that momentum has been building rather than fading around these latest announcements.

Scan how Fresenius SE KGaA compares with other health care stocks showing strong momentum and robust financial profiles by reviewing our hand picked 200 high quality undervalued stocks.

After a 26.24% one month surge and fresh momentum around the WuXi Biologics deal, the real tension now is timing. Is Fresenius SE KGaA better approached on this breakout, or on a cooler pullback once valuation is clear?

Most Popular Narrative: 3.8% Undervalued

Fresenius SE KGaA closed at €53.47 compared with an analyst consensus fair value of €55.59. The analyst consensus Narrative on Simply Wall St is framed using detailed earnings, margin and reinvestment assumptions built around Kabi and Helios.

The build out of the biosimilars franchise, including high market shares for Tyenne and the denosumab biosimilar and new products like rituximab and the vedolizumab candidate, positions future Biopharma sales and EBIT margin progress as a potential driver of higher group earnings.

See why 36 investors see Fresenius SE KGaA as 4% undervalued.

Result: Fair Value of €55.59 (UNDERVALUED)

Still, the Fresenius SE KGaA narrative can be knocked off course if cost inflation bites into Helios and Kabi margins, or if Chinese procurement pressure keeps earnings below analyst expectations.

Find out about the key risks to this Fresenius SE KGaA narrative.

Next Steps

Mixed views on whether Fresenius SE KGaA is on the verge of a stronger rerating or already pricing in a lot of good news. Move quickly, review the detailed risks and potential bright spots, then weigh up the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Fresenius SE KGaA?

Do not stop at a single opportunity. Fresh ideas often come from scanning wider markets, spotting patterns across sectors, and then focusing on what truly fits your plan.

• Target income you can actually see by reviewing companies screened as 221 dividend fortresses that may suit investors who want yield alongside resilient business models.
• Look for quality at a sensible entry point with our focused set of 200 high quality undervalued stocks that combine stronger fundamentals with appealing price tags.
• Protect your capital first by concentrating on 208 resilient stocks with low risk scores that prioritise balance sheet strength and lower overall risk scores.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com